nQ Medical and EvergreenHealth Looking for Early Parkinson's Disease Patients to Participate in First Pivotal Study of Remote Digital Assessment Tool Using Naturalistic Typing
Kirkland, Wash. – In a first of its kind study, nQ Medical and EvergreenHealth will be evaluating a prospective new device that utilizes natural typing activity as a method of better assessing and characterizing the consistency and severity of symptoms for people living with Parkinson’s Disease (PD) between in-person clinical visits. This novel, non-invasive method of assessment can accurately characterize PD motor symptoms from remote, passively collected natural typing data. The data the device generates will be compared to commonly used physician scales for PD assessment and management.
The study will enroll approximately 50 participants and will be conducted at the Booth Gardner Parkinson’s Care Center at EvergreenHealth starting in July. To be eligible for the study, participants must be diagnosed with PD within the last 10 years; be willing to install the proprietary application on their PC for the 4-week study duration; and use their PC for at least 15 minutes per day on average during the study. Compensation for participation will be provided.
“This is an exciting opportunity to help make a difference in how Parkinson’s Disease symptoms are monitored and managed. We know that every day can bring a new or different challenge to those living with PD. Effective symptom management of this condition is very important and that starts with having the ability to accurately understand each patient’s symptoms in between visits. We’re thankful for the scientists and patients who dedicate their time to this important body of research,” said Pinky Agarwal, MD, EvergreenHealth Booth Gardner Parkinson’s Care Center.
Currently, clinicians are limited in their ability to gather reliable, consistent and objective data to help make fully comprehensive, informed treatment decisions. During a physical examination, clinicians are able to directly observe patient symptoms and function. However, these examinations only offer periodic snapshots which leave longer periods of time where motor impairments and function are not directly monitored. As a result, physicians must rely on patients and care givers to accurately fill in the gaps over time frames when PD symptoms are known to fluctuate, which can lead to necessary changes in treatment going unidentified.
To gather objective data about the severity and consistency of symptoms in PD patients in between in-person visits, the nQ Medical software tool assess aspects of fine motor performance during natural typing on personal computers. Compatible with both Apple- and Windows-based personal computers (PCs), nQ Medical’s application uses remotely collected typing data to characterize aspects of motor function from streams of continuous typing. Unlike a keylogger, nQ’s application monitors how you type and not what you type; using a machine learning enhanced method of analysis, the device looks for subtle patterns in the cadence of typing that are clinically useful.
Parkinson’s Disease (PD) is the most common movement disorder in Washington State besides essential tremor and the second most prevalent neurodegenerative disorder in the western world. There are nearly 1 million people in the United States affected by this disease, and more than 6 million people worldwide.
PD is commonly characterized by the presence of classic motor impairments—tremor, bradykinesia, rigidity, postural instability and gait difficulty—resulting from the loss of nigrostriatal dopaminergic neurons in the central nervous system. Subtle motor manifestations in the early phases of PD can precede the clinical diagnosis by several years and following the diagnosis, motor impairment and fluctuations in motor function become increasingly prevalent, making it difficult for people with PD to manage common daily activities on a regular basis. There are currently no disease modifying agents approved for the treatment of PD. Symptom management is key to supporting the best possible quality of life for those living with PD.
“This study is tremendously important to the PD community. Having more thorough, long-term, objective data that tells the full-spectrum story about a patient’s symptoms overtime means that we can make even more informed decisions about the next steps in their care plan for PD symptom management. I am very hopeful this device will have a profound impact on PD symptom insight and ultimately, patient care,” said Rich Bavasso, Founder and CEO, nQ Medical.
Those interested in participating and may be eligible are invited to contact the EvergreenHealth research team at EvergreenHealth 425.899.5385.
About nQ Medical
nQ Medical, Inc. is a Digital Biomarker Discovery Platform of data modeling that can be adapted cross-disorder and readied for rapid scaling. nQ Medical’s AI-powered computational biomarker yields powerful insights. We believe that the way our fingers interact with smart phones and computers can reveal the presence of certain neuromotor and neurocognition diseases like Parkinson’s, Alzheimer’s, ALS, and Multiple Sclerosis. The fine control of typing and touch screen kinematics, as well as the frequent use of personal devices like smartphones brings Real World Data to patients, caregivers, and clinicians. For more information, please contact us: https://www.nQ-Medical.com/